# TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer

> **NCT03287674** · PHASE1,PHASE2 · COMPLETED · sponsor: **Inge Marie Svane** · enrollment: 7 (actual)

## Conditions studied

- Metastatic Ovarian Cancer

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** TIL infusion
- **DRUG:** Interleukin-2
- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT03287674
- **Lead sponsor:** Inge Marie Svane
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-09
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287674, "TIL Therapy in Combination With Checkpoint Inhibitors for Metastatic Ovarian Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03287674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*